Core Viewpoint - The article highlights the recent developments and achievements of Nanjing Pulimeng Medical Technology Co., Ltd., including a successful C-round financing of nearly 300 million yuan, aimed at enhancing product development and market expansion in the medical field [2][7]. Company Overview - Nanjing Pulimeng, established in 2016, focuses on medical polymer materials and bioengineering, positioning itself as a platform for the intersection of material science and clinical medicine [3]. - The company has overcome significant challenges in medical materials, establishing key technology platforms for the engineering preparation of biodegradable polymer materials and personalized processing of biodegradable medical devices [3]. - As of now, Pulimeng has obtained nearly 30 NMPA registration certificates, with 11 of them being Class III certificates [3]. Main Products and Technologies - Pulimeng has developed a robust matrix in the field of surgical sutures, addressing clinical application needs across various scenarios [4]. - The flagship product, "absorbable knotless barbed suture," is made from poly(p-dioxanone) (PPDO) and features a 360-degree spiral barbed cutting design, with a degradation period of approximately 180 days, simplifying the suturing process in minimally invasive surgeries [4][6]. - The company has also launched a full range of barbed suture products, including "fast-absorbing barbed sutures," "non-absorbable barbed sutures," and "fishbone sutures," achieving rapid commercial growth [6]. Financing History - Pulimeng has undergone several financing rounds, including an A-round in 2022, raising nearly 100 million yuan, and a B-round in 2023, securing close to 200 million yuan [7]. - The recent C-round financing in August 2025 raised nearly 300 million yuan, with participation from multiple investors, including Yahui Investment and Huatai Zijin [2][7].